drugset / Trial / NCT05384249
Phase 2b Pivotal Study of Izokibep in Non-infectious, Intermediate-, Posterior- or Pan-uveitis
RandomizedParallel-groupDouble-blindTreatment
Summary
Izokibep is a small protein molecule that acts as a selective, potent inhibitor of interleukin-17A, to which it binds with high affinity. This study investigates izokibep in subjects with active non-infectious, intermediate-, posterior- or pan-uveitis requiring high-dose steroids.
Timeline
- Start
- 2022-08-23
- Primary completion
- 2025-02-07
- Completion
- 2025-02-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Izokibep | Protein / enzyme biologic | — | Subcutaneous |